Literature DB >> 21170281

Kidney after Extrarenal Transplantation - The Impact of Alemtuzumab Induction.

Ron Shapiro1, Amit Basu, Henkie P Tan, Claire Morgan, Vivek Sharma, Deanna Blisard, Parmjeet S Randhawa, Igor Dvorchik, Jerry McCauley, Demetrius Ellis, J Wallis Marsh, Steven Webber, Geoffrey Kurland, Kenneth McCurry, Kareem Abu-Elmagd, George Mazariegos, Thomas E Starzl.   

Abstract

Entities:  

Year:  2008        PMID： 21170281      PMCID： PMC3002172     

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  10 in total

1.  Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients.

Authors:  R Calne; P Friend; S Moffatt; A Bradley; G Hale; J Firth; J Bradley; K Smith; H Waldmann
Journal:  Lancet       Date:  1998-06-06       Impact factor: 79.321

2.  Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy.

Authors:  H P Tan; D J Kaczorowski; A Basu; M Unruh; J McCauley; C Wu; J Donaldson; I Dvorchik; L Kayler; A Marcos; P Randhawa; C Smetanka; T E Starzl; R Shapiro
Journal:  Am J Transplant       Date:  2006-08-04       Impact factor: 8.086

3.  Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath.

Authors:  Ron Shapiro; Amit Basu; Henkie Tan; Edward Gray; Akhtar Kahn; Parmjeet Randhawa; Noriko Murase; Adriana Zeevi; Alin Girnita; Diana Metes; Roberta Ness; Debra C Bass; Anthony J Demetris; John J Fung; Amadeo Marcos; Thomas E Starzl
Journal:  J Am Coll Surg       Date:  2005-04       Impact factor: 6.113

4.  Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation.

Authors:  Ron Shapiro; Demetrius Ellis; Henkie P Tan; Michael L Moritz; Amit Basu; Abhay N Vats; Akhtar S Khan; Edward A Gray; Adrianna Zeevi; Corde McFeaters; Gerri James; Mary Jo Grosso; Amadeo Marcos; Thomas E Starzl
Journal:  J Pediatr       Date:  2006-06       Impact factor: 4.406

5.  Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles.

Authors:  Bijan Eghtesad; John J Fung; Anthony J Demetris; Noriko Murase; Roberta Ness; Debra C Bass; Edward A Gray; Obaid Shakil; Bridget Flynn; Amadeo Marcos; Thomas E Starzl
Journal:  Liver Transpl       Date:  2005-11       Impact factor: 5.799

6.  Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).

Authors:  Allan D Kirk; Douglas A Hale; Roslyn B Mannon; David E Kleiner; Steven C Hoffmann; Robert L Kampen; Linda K Cendales; Douglas K Tadaki; David M Harlan; S John Swanson
Journal:  Transplantation       Date:  2003-07-15       Impact factor: 4.939

7.  Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study.

Authors:  Stuart J Knechtle; John D Pirsch; John H Fechner; Bryan N Becker; Andreas Friedl; Robert B Colvin; Lauralynn K Lebeck; L Thomas Chin; Yolanda T Becker; Jon S Odorico; Anthony M D'Alessandro; Munci Kalayoglu; Majed M Hamawy; Huaizhong Hu; Debra D Bloom; Hans W Sollinger
Journal:  Am J Transplant       Date:  2003-06       Impact factor: 8.086

8.  Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody.

Authors:  Ron Shapiro; Adriana Zeevi; Amit Basu; Henkie P Tan; Liise K Kayler; Deanna M Blisard; Ngoc L Thai; Alin L Girnita; Parmjeet S Randhawa; Edward A Gray; Amadeo Marcos; Thomas E Starzl
Journal:  Transplantation       Date:  2008-04-27       Impact factor: 4.939

9.  A personal history of the CAMPATH-1H antibody.

Authors:  Herman Waldmann
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

10.  Chronic renal failure after transplantation of a nonrenal organ.

Authors:  Akinlolu O Ojo; Philip J Held; Friedrich K Port; Robert A Wolfe; Alan B Leichtman; Eric W Young; Julie Arndorfer; Laura Christensen; Robert M Merion
Journal:  N Engl J Med       Date:  2003-09-04       Impact factor: 91.245
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.